Clinical Experience of Raltegravir with Abacavir/Lamivudine or Zidovudine/Lamivudine in HIV-Infected Korean Adults
-
- Kang Seung-Ji
- Department of Internal Medicine, Chonnam National University Medical School
-
- An Joon Hwan
- Department of Internal Medicine, Chonnam National University Medical School
-
- Kim Jin
- Department of Internal Medicine, Chonnam National University Medical School
-
- Jang Mi Ok
- Department of Internal Medicine, Chonnam National University Medical School
-
- Kim Seong Eun
- Department of Internal Medicine, Chonnam National University Medical School
-
- Park Kyung-Hwa
- Department of Internal Medicine, Chonnam National University Medical School
-
- Jung Sook-In
- Department of Internal Medicine, Chonnam National University Medical School
-
- Jang Hee-Chang
- Department of Internal Medicine, Chonnam National University Medical School
この論文をさがす
抄録
The efficacy and safety of raltegravir (RAL) with tenofovir (TDF)/emtricitabine (FTC) have been well studied in human immunodeficiency virus (HIV)-infected patients. However, limited clinical data are available on the use of RAL with abacavir (ABC)/lamivudine (3TC) or zidovudine (ZDV)/3TC. We investigated HIV-1-infected Korean adults, including 13 antiretroviral-naïve patients and 15 antiretroviral-experienced patients, treated with RAL plus ABC/3TC or ZDV/3TC. Virological suppression was achieved in 12 of the 13 (92%) antiretroviral-naïve patients within 24 weeks and in all (100%) patients within 96 weeks. In 13 of the 15 treatment-experienced patients, ritonavir-boosted lopinavir (LPV/r) was replaced with RAL because of hyperlipidemia (n = 11) and diarrhea (n = 2). A significant decrease in median total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels was observed in these patients (P < 0.01, each). No adverse event related to RAL was observed in any of the 28 patients. The RAL plus ABC/3TC or ZDV/3TC regimens were effective and safe in antiretroviral-naïve Korean HIV-infected patients, and replacing LPV/r with RAL significantly improved lipid abnormalities in patients previously treated with regimens including LPV/r.
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 66 (4), 317-319, 2013
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681217851776
-
- NII論文ID
- 130003381695
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 024716462
-
- PubMed
- 23883843
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可